Clinical trials
Phase 1 Biliary Tract Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
54 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 3 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 5 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 6 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Recruiting | 19 |
| Terminated | 6 |
| Unknown status | 4 |
| Active, not recruiting | 2 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 3 |
| Kansai Hepatobiliary Oncology Group | 3 |
| AbbVie | 2 |
| SystImmune Inc. | 2 |
| University of California, San Francisco | 2 |
| ASLAN Pharmaceuticals | 1 |
| AbGenomics B.V Taiwan Branch | 1 |
| Array Biopharma, now a wholly owned subsidiary of Pfizer | 1 |
| Black Diamond Therapeutics, Inc. | 1 |
| Carisma Therapeutics Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biliary Tract Neoplasms | 54 |
| Stomach Neoplasms | 17 |
| Colorectal Neoplasms | 16 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Pancreatic Neoplasms | 12 |
| Cholangiocarcinoma | 11 |
| Breast Neoplasms | 10 |
| Endometrial Neoplasms | 10 |
| Carcinoma, Hepatocellular | 7 |
| Neoplasm Metastasis | 7 |
Trials
Showing 51 to 54 of 54. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.